Pumpinheart

Pumpinheart is a heart failure treatment system with preserved ejection fraction (HFpEF).

ActiveMedical Device

Updated: Feb 17, 2026 ·

About

Pumpinheart is an Irish medical device company dedicated to addressing Heart Failure with preserved Ejection Fraction (HFpEF), a condition identified as an unmet medical need. The company is developing a novel device specifically designed to treat HFpEF, aiming to provide a new therapeutic option for patients.

Operating from locations such as Galway and Dublin, Ireland, Pumpinheart is active in the medical technology landscape. The company has also participated in accelerator programs, including the Health Wildcatters 2025 Accelerator, to advance its product development and market readiness.

Recent News & Mentions

Feb 10, 2026FundingPumpinheart - Seed

Financial History

Pumpinheart has raised $832K across 1 funding round. Most recently, it raised $832K Seed in February 2026.

Total Raised

$832K

Valuation

N/A

Funding Rounds Raised

Date	Round	Lead Investors	Other Investors
Feb 10, 2026	$832K Seed

Financial History

Pumpinheart has raised $832K across 1 funding round.

Total Raised

$832K

Valuation

N/A

Deep Dive

Pumpinheart is a medical device company focused on developing innovative solutions for Heart Failure with preserved Ejection Fraction (HFpEF). This specific type of heart failure represents a significant unmet medical need, driving Pumpinheart's mission to create effective treatments.

The company's primary offering is a novel medical device engineered to treat HFpEF. This device is being developed to provide a targeted therapeutic approach for patients, aiming to improve outcomes for individuals living with this challenging condition.

Leadership within Pumpinheart includes Dr. Aamir Hameed, who serves as a Co-founder and Chief Medical Officer. Dr. Hameed brings medical expertise to the company's development efforts, contributing to the clinical direction of its device.

Headquartered in Ireland, with operations noted in Galway and Dublin, Pumpinheart is part of the country's growing medical technology sector. The company has also expanded its engagement within the broader venture ecosystem by joining the Health Wildcatters 2025 Accelerator, based in Dallas, Texas.

Pumpinheart's strategic focus on HFpEF underscores its commitment to addressing complex cardiovascular diseases with specialized medical device technology. Its participation in accelerator programs indicates a proactive approach to development and potential market entry.

Sources

Frequently Asked Questions

What specific medical condition does Pumpinheart aim to address?

Pumpinheart is developing a medical device to treat Heart Failure with preserved Ejection Fraction (HFpEF), which is identified as an unmet medical need.

Where is Pumpinheart primarily based?

Pumpinheart is based in Ireland, with operations noted in locations such as Galway and Dublin.

What accelerator program has Pumpinheart joined?

Pumpinheart joined the Health Wildcatters 2025 Accelerator, which is located in Dallas, Texas.